Expected Net Present Value of Sample Information: from burden to investment
The Expected Value of Information Framework has been proposed as a method for identifying when health care technologies should be reimbursed and when reimbursement should be withheld awaiting more evidence. The standard framework assesses the value of having additional evidence available to inform a current reimbursement decision. This can be thought of as the burden of not having the additional evidence available at the time of the decision. However, the information that decision makers need to decide whether to reimburse now or await more evidence is the value of investing in the creation of the new evidence to inform a future decision. Assessing the value requires the analysis to incorporate the costs of the research, the time it will take for the research to report and what happens to patients whilst the research is undertaken and once it has reported. In this paper we describe a development of the calculation of the expected value of sample information that assesses the value of investing in further research using (a) an only-in-research strategy; and (b) an only-with-research strategy.
|Date of creation:||2011|
|Publication status:||Published in Medical Decision Making, May-June 2012, Vol 32 no. 3, pages E11-E21|
|Contact details of provider:|| Phone: Worsley Building, Level 11, Clarendon Way, LEEDS LS2 9NL|
Fax: +44 (0) 113 343 3470
Web page: http://medhealth.leeds.ac.uk/auhe
More information through EDIRC
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Simon Eckermann & Andrew R. Willan, 2007. "Expected value of information and decision making in HTA," Health Economics, John Wiley & Sons, Ltd., vol. 16(2), pages 195-209.
- Jeremy E. Oakley & Anthony O'Hagan, 2004. "Probabilistic sensitivity analysis of complex models: a Bayesian approach," Journal of the Royal Statistical Society Series B, Royal Statistical Society, vol. 66(3), pages 751-769.
- J. Kirsch & A. McGuire, 2000. "Establishing health state valuations for disease specific states: an example from heart disease," Health Economics, John Wiley & Sons, Ltd., vol. 9(2), pages 149-158.
- Claxton, Karl, 1999. "The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies," Journal of Health Economics, Elsevier, vol. 18(3), pages 341-364, June.